Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Galmed Pharmaceuticals Ltd. - Ordinary Shares (NQ:GLMD)

0.5930 -0.0113 (-1.87%)
Streaming Delayed Price Updated: 2:05 PM EDT, Jun 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Galmed Pharmaceuticals Ltd. - Ordinary Shares

< Previous 1 2 3 4 Next >
News headline image
Galmed Pharmaceuticals Q4 2021 Earnings Conference Call On May 2, 2022 At 08:30 AM ET ↗
Galmed Pharmaceuticals (NASDAQ:GLMD) will host a conference call at 08:30 AM ET on May 2, 2022, to discuss Q4 2021 earnings results. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗
Good morning, trader! Let's start off the final day of the workweek right with a breakdown of the biggest pre-market stock movers for Friday! 
Via InvestorPlace
News headline image
25 Stocks Moving in Friday's Pre-Market Session ↗
Gainers Grom Social Enterprises, Inc. (NASDAQ: GROM) rose 60.5% to $1.53 in pre-market trading. StoneCo Ltd. (NASDAQ: STNE) shares rose 23.7% to $11.90 in pre-market trading... 
Via Benzinga
News headline image
Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study ↗
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) posted results of the Phase 1 trial of Amilo-5MER in healthy volunteers. Amilo-5MER is a synthetic peptide consisting of... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
News headline image
Galmed's NASH Candidate Shows Clinically Significant Effect On Fibrosis Improvement ↗
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has announced histology and biomarkers analysis results from the Ongoing Open-Label Part of the ARMOR Phase 3 study of... 
Via Benzinga
News headline image
26 Stocks Moving in Monday's Pre-Market Session ↗
Gainers Autolus Therapeutics plc (NASDAQ: AUTL) rose 32.6% to $7.37 in pre-market trading. Syncona said Blackstone Life Science will invest $250 million in Autolus. Mainz Biomed... 
Via Benzinga
News headline image
Galmed Reveals Early Aramchol Data From Late-Stage NASH Trial ↗
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) announced results from the first 16 patients in the Open-Label Part of the ARMOR Phase 3 study who underwent a scheduled... 
Via Benzinga
News headline image
Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action ↗
Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) has announced the data publication for its preclinical compound, Amilo-5MER, in the Journal of Autoimmunity. Amilo-5MER... 
Via Benzinga
News headline image
40 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares jumped 133% to $5.27 after the company announced a $5 million stock repurchase program. Exicure, Inc. (NASDAQ:... 
Via Benzinga
News headline image
61 Biggest Movers From Yesterday ↗
Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares climbed 124.8% to close at $5.08 on Monday after the company announced a $5 million stock repurchase program.... 
Via Benzinga
News headline image
Galmed Stock Jumps As FDA Signs Off Use Of Aramchol Meglumine In Late Stage NASH Trial ↗
The FDA has agreed with Galmed Pharmaceuticals Ltd's (NASDAQ: GLMD) plan to use Aramchol meglumine (instead of Aramchol free acid) in its Phase 3 ARMOR... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs ↗
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
News headline image
28 Stocks Moving in Wednesday's Pre-Market Session ↗
Gainers Aethlon Medical, Inc. (NASDAQ: AEMD) rose 72.4% to $3.81 in pre-market trading following Zacks article 'AEMD: First Ever In Vivo Removal Of COVID Virus From... 
Via Benzinga
News headline image
60 Biggest Movers From Yesterday ↗
Gainers Ra Medical Systems, Inc. (NYSE: RMED) shares surged 87.3% to close at $9.14 on Monday on abnormally-high session volume. EXFO Inc. (NASDAQ: EXFO) gained 60.3% to settle... 
Via Benzinga
News headline image
35 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Ra Medical Systems, Inc. (NYSE: RMED) shares jumped 64.8% to $8.04 on abnormally-high session volume. EXFO Inc. (NASDAQ: EXFO) surged 60.3% to $5.93 after the company... 
Via Benzinga
News headline image
22 Stocks Moving in Monday's Pre-Market Session ↗
Gainers Liminal BioSciences Inc. (NASDAQ: LMNL) rose 51.7% to $6.10 in pre-market trading. Liminal BioSciences reported the FDA approval for its Biologics License Application... 
Via Benzinga
News headline image
Week In Review: WHO Close To Approving Global Use For Two China COVID-19 Vaccines ↗
The World Health Organization approved Sinopharm's COVID-19 vaccine for emergency use, which will give poorer nations access to a vaccine against the pandemic. Sinovac's inactivated COVID-19 vaccine... 
Via Talk Markets
News headline image
64 Biggest Movers From Friday ↗
Gainers Senseonics Holdings, Inc. (NYSE: SENS) jumped 42% to settle at $2.91 on Friday after the company disclosed results from a PROMISE study evaluating its Eversense CGM... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
Gainers Obalon Therapeutics (NASDAQ:OBLN) shares moved upwards by 6.04% to $2.63 during Monday's after-market session. At the close, Obalon Therapeutics's trading volume... 
Via Benzinga
News headline image
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 12) Alexion Pharmaceuticals, Inc... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... 
Via Benzinga
News headline image
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings ↗
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 6) GT Biopharma, Inc. (NASDAQ:... 
Via Benzinga
News headline image
72 Biggest Movers From Yesterday ↗
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 85.8% to settle at $10.22 on above-average volume. Liquidity Services, Inc. (NASDAQ: LQDT) jumped 37.7% to settle at $25... 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.